Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG-b-P[Asp(DET)] is a **polymer-drug conjugate** consisting of **poly(ethylene glycol) (PEG)** covalently linked in a block copolymer structure to **poly(aspartamide) (PAsp) chains functionalized with diethylenetriamine (DET) groups**. This copolymer is engineered to form micelles for drug delivery, especially nucleic acids like siRNA or plasmid DNA[3]. The PEG segment provides steric stabilization, biocompatibility, and extends circulation time in vivo, while the P[Asp(DET)] segment offers cationic charge for complexation with negatively charged nucleic acids. In acidic environments (e.g., tumor tissue or endosomes), the DET groups are protonated, which triggers membrane destabilization, improved endosomal escape, and efficient intracellular delivery. This pH-sensitive feature enhances the release profiles and gene silencing activity of loaded nucleic acids[3]. PEG-b-P[Asp(DET)] does not act directly on molecular targets but functions as a **non-viral gene delivery carrier**. It has been developed primarily in academic settings for nanomedicine research and preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PEG-b-P[Asp(DET)].